Guggenheim Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $35

Guggenheim analyst Brad Canino maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $38 to $35.